// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























28841 Abstracts

The Effect of Angiotensin II (ANG II) Infusion on Plasma Uric Acid (PUA) in Patients with Type 1 Diabetes (T1D)

YULIYA LYTVYN - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Type 1 diabetes mellitus

Angiotensin II

Copeptin and Renin Angiotensin Aldosterone System (RAAS) Activation in Long-Standing Type 1 Diabetes (T1D)

PETTER BJORNSTAD - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Diabetic nephropathy

Angiotensin II

Baroreflex Function and Postprandial Hypotension in Older Adults With and Without Type 2 Diabetes

KENNETH M. MADDEN - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Type 2 diabetes mellitus

Methadone hydrochloride

A Delphi Study

SAPNA SHAH - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Diabetes

N/A

Validation of the Diabetes Knowledge Test and the Diabetes Attitude Scale 3, in a Diabetic Population in Venezuela

YAMILETH MARCANO - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Diabetes

N/A

Assessment of Individual Self-Management Using the Novel LMC Skills, Confidence, and Preparedness Index (SCPI)

RONNIE ARONSON - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Exercise Training Alters Subcutaneous Adipose Tissue Morphology in Obese Adults Even without Weight Loss

CHIWOON AHN - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Obesity

N/A

Announced and Unannounced Exercise

SEMAH TAGOUGUI - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Type 1 diabetes mellitus

N/A

Preliminary Results

SEMAH TAGOUGUI - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Effect of Morning (Fasting) vs. Afternoon High-Intensity Interval Exercise on Blood Glucose in Type 1 Diabetes

JANE E. YARDLEY - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Type 1 diabetes mellitus

N/A

Exercise Training Does Not Alter Resting Fatty Acid Mobilization from Adipose Tissue

MICHAEL W. SCHLEH - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Obesity

Palmitic acid

Accuracy of Energy Expenditure Measurements by Activity Monitors in Type 1 Diabetes and Control Subjects

RUBIN POONI - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Type 1 diabetes mellitus

N/A

More Time-in-Range during Days with Structured Exercise vs. Sedentary Days in Adults with Type 1 Diabetes

MICHAEL RIDDELL - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Type 1 diabetes mellitus

N/A

"I Had Nobody to Represent Me"—How Patient Perceptions of Diabetes Health Care Providers' Age, Gender, and Ethnicity Impact Shared Decision-Making

TEHMINA AHMAD - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

N/A

Utilities to Measure Valuation of Diabetes in Haiti

CLEMENT BELANGER-BISHINGA - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Diabetes

N/A

Results from COMRADE

DOYLE M. CUMMINGS - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Type 2 diabetes mellitus

N/A

Canada Real-World Analysis of Flash Glucose Monitoring and Impact on Time-in-Range and Hypoglycemia

LORI BERARD - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Diabetes

N/A

Diabits—An AI-Powered Smartphone Application for Blood Glucose Monitoring and Predictions

AMIR HAYERI - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

N/A

Do Baseline Characteristics Impact Efficacy of Efpeglenatide QW in Uncontrolled Type 2 Diabetes?

GEORGE E. DAILEY III - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Type 2 diabetes mellitus

Efpeglenatide

A Subanalysis of EXCEED 203

JULIO ROSENSTOCK - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Efpeglenatide

Copyright © 2026. QuantiNova All rights reserved